Significant events unfolding for Alnylam Pharmaceuticals, as it presented at the Piper Sandler 36th Annual Healthcare Conference. Various asset management firms, including Eventide Asset Management and Suvretta Capital Management, have invested millions in Alnylam stock, despite CFO, CEO, CSO and other leadership figures selling their share holdings. RNAi renaissance is stirring, paving way for biotech startups. The FDA has started to review Alnylam's sNDA for the Amvuttra expansion, a treatment for ATTR Amyloidosis with Cardiomyopathy.
Alnylam showed promising indices in its latest quarterly financial reports, revealing a notable growth in revenue. The firm is also strengthening its strategic partnerships, including its collaboration with Cognizant to scale IT operations and the expansion with Medison Pharma for the distribution of RNAi therapeutics in several international markets. Its drug Nucresiran showed sustained TTR reduction even six months after a single dose. Vutrisiran achieved statistical significance on primary and all secondary endpoints in its HELIOS-B Phase 3 study. Despite facing competition in the market, the company has maintained an overall bullish outlook.
Alnylam Pharmaceuticals News Analytics from Tue, 30 Apr 2024 07:00:00 GMT to Sat, 30 Nov 2024 14:04:41 GMT - Rating 6 - Innovation 7 - Information 8 - Rumor -2
